UFC flyweight Alibi Idiris has been handed a one-year suspension after violating the organization’s anti-doping rules, the UFC confirmed Tuesday. The violation came after Idiris tested positive for hydrochlorothiazide, a diuretic banned under the UFC’s Prohibited List, in an in-competition sample collected during fight week for his February 21, 2026, bout in Houston, Texas, where he defeated Ode Osborne by unanimous decision.
Idiris disclosed that he took a product containing the diuretic on February 20, the day before the official weigh-in, to aid in making weight. Although he fully cooperated with Combat Sports Anti-Doping (CSAD), the agency emphasized that the suspension would not be reduced due to the deliberate use of a weight-cutting diuretic and the competitive advantage it provided. The suspension began on February 21, 2026, and will end on February 21, 2027.
UFC Flyweight Alibi Idiris Receives One-Year Suspension Following Anti-Doping ViolationUFC Suspends Alibi Idiris, Highlighting Rules Enforcement and Career Setback
The UFC’s ruling is expected to result in Idiris’s win over Osborne being overturned to a no-contest, pending review by the Texas Department of Licensing and Regulations, which is overseeing the case.
Idiris, 31, joined the UFC in 2025 after reaching the finals of The Ultimate Fighter 33 flyweight tournament. He currently holds an 11-1 professional MMA record, with his only loss coming to Joseph Morales in the TUF 33 finale. The suspension represents a major setback early in his UFC career, interrupting the momentum he had built after his strong debut season.
While Idiris’s transparency and cooperation were acknowledged, the UFC and CSAD reinforced that the use of diuretics in competition constitutes a serious breach of anti-doping rules. The case highlights the organization’s commitment to maintaining fairness, fighter safety, and the integrity of competition in mixed martial arts.
